Insider filing
Traded Jun 11 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded May 14, 2026 · Filed May 16, 2026
The CEO of United Therapeutics sold $215K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$214,710
Shares × reported transaction price
8 days after results of May 6, 2026, 83 days before results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $575.79 on May 14, 2026, within 4% of its 52-week high, little changed over the previous 30 trading days
52-week range $274.70 (Jul 31, 2025) to $596.76 (May 6, 2026), 93% of the way up, from 251 adjusted closes. 30 trading days earlier: $570.27 on Apr 1, 2026. Describes the past only, not a forecast
RSI 53, 23% above its 200-day average, 3% above its 50-day average, 4% below the 52-week high, 20-day volatility 29% a year, against the S&P 500: −7 points over 1 month, +11 points over 3 months, +16 points over 6 months
From the adjusted closes up to May 14, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.0% | +1.6% | +0.4% |
| 30 days | −2.7% | +0.3% | −3.0% |
| 90 days | −10.3% | +4.6% | −14.9% |
| 180 days | +3.7% | +0.2% | +3.5% |
Past results only. Not a forecast.
Insider filing
Traded Jun 11 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
James Edgemond (CFO AND TREASURER) sold ~$25K of United Therapeutics
Planned saleJames Edgemond (CFO AND TREASURER) sold ~$84K of United Therapeutics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.